BioHarvest Sciences’ (BHST) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of BioHarvest Sciences (NASDAQ:BHST) in a research report report published on Tuesday,Benzinga reports. They currently have a $14.00 price objective on the stock. HC Wainwright also issued estimates for BioHarvest Sciences’ Q1 2025 earnings at ($0.13) EPS, Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at $0.01 EPS, FY2025 earnings at ($0.27) EPS, FY2026 earnings at $0.05 EPS, FY2027 earnings at $0.32 EPS, FY2028 earnings at $0.69 EPS and FY2029 earnings at $1.15 EPS.

Separately, Maxim Group began coverage on shares of BioHarvest Sciences in a research report on Wednesday, December 18th. They set a “buy” rating and a $12.00 target price for the company.

BioHarvest Sciences Trading Up 2.8 %

BHST stock opened at $5.55 on Tuesday. BioHarvest Sciences has a 1 year low of $5.40 and a 1 year high of $7.38. The stock has a market cap of $91.16 million, a P/E ratio of -4.44 and a beta of 0.84. The business has a fifty day moving average price of $5.74.

BioHarvest Sciences (NASDAQ:BHST) last announced its earnings results on Monday, March 31st. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.05). The business had revenue of $7.17 million during the quarter, compared to analyst estimates of $7.24 million. Sell-side analysts expect that BioHarvest Sciences will post -0.8 earnings per share for the current year.

Institutional Trading of BioHarvest Sciences

An institutional investor recently bought a new position in BioHarvest Sciences stock. TD Waterhouse Canada Inc. bought a new position in BioHarvest Sciences Inc. (NASDAQ:BHST) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 12,042 shares of the company’s stock, valued at approximately $69,000. TD Waterhouse Canada Inc. owned approximately 0.07% of BioHarvest Sciences at the end of the most recent quarter.

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.